St. Jude Children's Research Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, St. Jude Children's Research Hospital sits in the top decile of US sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count).
St. Jude Children's Research Hospital: 410 sponsored US clinical trials, 90 recruiting.
St. Jude Children's Research Hospital sponsors 410 registered US clinical trials on ClinicalTrials.gov, 90 of them currently recruiting, and 227 completed. 19 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 17 trials.
Top-decile sponsor footprint
St. Jude Children's Research Hospital ranks in the top decile of sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
227 of 259 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
410 total, page 4 of 9
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
NCT07585136
RESPECT: (REsearching Stigma in PEdiatric Cancer Tool)
NCT06470230
Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding
NCT05685199
Parents Reflecting On Hope During Hospice Through Photovoice
NCT06187636
Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer
NCT05746429
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
NCT05579769
Early Detection of Endotheliopathy Post-Transplant
NCT05594251
Exploring The Role Of Palliative Care In Phase 1 Enrolled Pediatric Oncology Patients
NCT05412563
Revealing Information Genuinely & Honestly Across Time: Pediatric Oncology Stakeholder Preferences and Recommendations for Prognostic Communication
NCT05116566
Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
NCT05044845
Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood
NCT04848142
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
NCT04410042
Immunologic Features of Respiratory Failure in Pediatric Hematopoietic Cell Transplantation (HCT) Recipients and Pediatric Oncology Patients
NCT04355780
eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer
NCT04317742
Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
NCT04401267
St. Jude Tracking of Viral and Host Factors Associated With COVID-19
NCT04362995
Prevention of Oral Mucositis Using Photobiomodulation Therapy
NCT04227340
Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)
NCT04007601
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
NCT04080167
Protocol For Collecting Long-Term Follow-Up Data On Recipients of Bone Marrow and Blood Stem Cell Transplant
NCT00674882
Trial of Antibody Responses by Vitamin Supplementation
NCT03859687
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
NCT04023669
T-cell Responses to Concurrent HIV and Herpesvirus Infections
NCT03996018
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
NCT03825341
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
NCT03913559
Antibiotic Resistance in Global Pediatric Oncology Centers
NCT03721562
Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)
NCT03838627
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas
NCT03696355
Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals
NCT03581045
Predictors and Outcomes in Patients With Sickle Cell Disease
NCT03431935
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
NCT03570411
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03515200
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
NCT03016156
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
NCT03434262
Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients
NCT03330080
Components of Social Functioning in Survivors of Pediatric Brain Tumors
NCT03361033
Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies
NCT03276702
Re-Aiming at Hydroxyurea Adherence for Sickle Cell With mHealth
NCT03344900
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
NCT03194906
Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI
NCT03187977
Validation Study of Pediatric Patient-Reported Outcomes
NCT03229837
Development of the Pediatric Neurocognitive Functioning Questionnaire
NCT03213431
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
NCT03194932
Feasibility of Isolating P16 Expression
NCT03160768
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
NCT03020615
Genetic Study of Familial Acute Lymphoblastic Leukemia
NCT03067584
The Oronasal Microbiota in Pediatric Oncology Patients
NCT02949427
Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital
NCT02948335
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
NCT03006848
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT02518750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 86 |
| Phase 3 | 17 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the St. Jude Children's Research Hospital pipeline
90 recruiting of 410 indexed (22% open); 227 completed (55%).
Phase mix: 19 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Jude Children's Research Hospital: open-pipeline peers nationwide
Peers matched on 410 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
St. Jude Children's Research Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 410 trials (± recruiting share)
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Rutgers, The State University of New Jersey · 413 trials · 26% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Northwell Health · 22% recruiting · 370 trials
- Vanda Pharmaceuticals · 22% recruiting · 68 trials
- Boston University Charles River Campus · 22% recruiting · 104 trials
- Regeneron Pharmaceuticals · 22% recruiting · 280 trials
Related
What to do with this St. Jude Children's Research Hospital page
410 registered trials is a research-attention snapshot, not an endorsement of St. Jude Children's Research Hospital or any single study.
- 90 of St. Jude Children's Research Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition St. Jude Children's Research Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
St. Jude Children's Research Hospital pipeline card: 410 registered trials from official public datasets.Report a data error.